Sign Out
Rheumatoid Arthritis: XELJANZ (tofacitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate (MTX).
Psoriatic Arthritis: XELJANZ is indicated for the treatment of adult patients with active psoriatic arthritis.
Ankylosing Spondylitis: XELJANZ is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy.
Ulcerative Colitis: XELJANZ is indicated for the induction and maintenance of treatment in adult patients with moderately to severely active ulcerative colitis (UC) with an inadequate response, loss of response or intolerance to corticosteroids, azathioprine (AZA), 6-mercaptopurine (6-MP) or tumor necrosis factor (TNF) antagonists.
Polyarticular Course Juvenile Idiopathic Arthritis: XELJANZ is indicated for the treatment of active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients with body weight ≥40 kg.
Continue with Google